Abstract
Purpose:
Benign prostatic hyperplasia (BPH), the most common benign neoplasm in American men, is a chronic condition that is associated with progressive lower urinary tract symptoms and affects almost 3 of 4 men during the seventh decade of life. Approximately 6.5 million of the 27 million white men who are 50 to 79 years old in the United States in 2000 were estimated to meet the criteria for discussing treatment.
Materials and Methods:
The analytical methods used to generate these results have been described previously.
Results:
In 2000 approximately 4.5 million visits were made to physician offices to for a primary diagnosis of BPH and almost 8 million visits were made with a primary or secondary diagnosis of BPH. In the same year approximately 87,400 prostatectomies for BPH were performed in inpatients in nonfederal hospitals in the United States. While the number of outpatient visits for BPH increased consistently during the 1990s, there was a dramatic decrease in the use of transurethral prostatectomy, inpatient hospitalization and length of hospital stay for this condition. These trends reflect the changing face of medical management for BPH, ie increasing use of pharmacological agents and minimally invasive therapies. In 2000 the direct cost of BPH treatment was estimated to be $1.1 billion exclusive of outpatient pharmaceuticals.
Conclusions:
Given the impact that BPH has on quality of life and health care cost in millions of American men, additional research into risk factors, diagnostic and therapeutic resource use, and effectiveness and cost benefit of therapies are warranted.
References
- 1 : A population-based study of health care-seeking behavior for treatment of urinary symptoms. The Olmsted County Study of Urinary Symptoms and Health Status Among Men. Arch Fam Med1993; 2: 729. Google Scholar
- 2 : Urologic Diseases in America Project: analytic methods and principal findings. J Urol2005; 173: 933. Link, Google Scholar
- 3 : Urologic Diseases in America Interim Compendium. Washington, D. C.: United States Department of Health and Human Services, Public Health Service, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases2004. Google Scholar
- 4 : Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U. S. men. Urology2002; 59: 877. Google Scholar
- 5 : The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol1993; 150: 85. Link, Google Scholar
- 6 : The natural history of lower urinary tract symptoms in black American men: relationships with aging, prostate size, flow rate and bothersomeness. J Urol2001; 165: 1521. Link, Google Scholar
- 7 : Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol1995; 153: 1510. Link, Google Scholar
- 8 : Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol1999; 161: 1174. Link, Google Scholar
- 9 : Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol1999; 162: 1301. Link, Google Scholar
- 10 : Natural history of prostatism: risk factors for acute urinary retention. J Urol1997; 158: 481. Link, Google Scholar
- 11 : Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol1999; 162: 376. Link, Google Scholar
- 12 : The diagnostic value of intravenous pyelography in infravesical obstruction in males. Scand J Urol Nephrol1977; 11: 225. Google Scholar
- 13 : Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research. Clin Pract Guidel Quick Ref Guide Clin1994; 8: 1. Google Scholar
- 14 : 1997 American Urological Association Gallup survey: changes in diagnosis and management of prostate cancer and benign prostatic hyperplasia, and other practice trends from 1994 to 1997. J Urol1998; 160: 1804. Link, Google Scholar
- 15 : AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol2003; 170: 530. Link, Google Scholar
- 16 : ARIA 3001,: Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology2002; 60: 434. Google Scholar
- 17 : Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int2003; 92: 257. Crossref, Medline, Google Scholar
- 18 : The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med2003; 349: 2387. Crossref, Medline, Google Scholar
- 19 : The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med1998; 338: 557. Crossref, Medline, Google Scholar
- 20 : Trends in prostatectomy for benign prostatic hyperplasia among black and white men in the United States: 1980 to 1994. Urology1999; 53: 1154. Google Scholar
- 21 : Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int2004; 93: 751. Google Scholar
From the Department of Urology, University of Michigan (JTW), Ann Arbor, Michigan, Department of Urology, Northwestern University (EC), Chicago, Illinois, and Division of Epidemiology, Mayo Clinic College of Medicine (SJJ), Rochester, Minnesota
